These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 38486856)

  • 1. Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions.
    Goutnik M; Iakovidis A; Still MEH; Moor RSF; Melnick K; Yan S; Abbas M; Huang J; Ghiaseddin AP
    Neurooncol Adv; 2024; 6(1):vdae025. PubMed ID: 38486856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
    J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
    Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
    Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
    Jindal V
    Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma.
    Liang T; Song Y; Gu L; Wang Y; Ma W
    Int J Gen Med; 2023; 16():4121-4141. PubMed ID: 37720174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
    Lin YJ; Mashouf LA; Lim M
    Front Immunol; 2022; 13():817296. PubMed ID: 35265074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Targets of CAR-T Cell Therapy for Glioblastoma.
    Wang C; Li Y; Gu L; Chen R; Zhu H; Zhang X; Zhang Y; Feng S; Qiu S; Jian Z; Xiong X
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
    Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
    Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
    Kringel R; Lamszus K; Mohme M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
    Feldman L; Brown C; Badie B
    Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future perspectives of chimeric antigen receptors against glioblastoma.
    Zhang J; Siller-Farfán JA
    Immunother Adv; 2022; 2(1):ltac014. PubMed ID: 36284838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.